anti-BAFF-R CAR T-cell therapy (Iaso Biotherapeutics/Nanjing University)

N/A

Report date: 2025/06/11 10:50:35

Base Information

Drug Nameanti-BAFF-R CAR T-cell therapy (Iaso Biotherapeutics/Nanjing University)
Drug Alias Nameanti-B-cell activating factor-receptor CAR T-cell therapy (Iaso Biotherapeutics/Nanjing University)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunostimulantsB-cell activating factor receptor modulatorsT lymphocytes stimulants
TargetsB-cell activating factor receptor
Therapy Area/IndicationsLymphoma, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing University
China Registration ClassN/A

Develop Information

Active CompaniesNanjing UniversityNanjing Iaso Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A